Anavex Life Sciences Corp (AVXL)

[sokol]

Yes, the more care and skill spent in identifying responders the more likely the success in obtaining approval, but this requires a great deal of work and study. Possibly a large number of candidates must be considered and screened to discover those that are more likely to respond. Anavex does not have to establish that AVXL 2-73 is effective for every possible, probable or proposed patient. It just has has to establish that it is effective for a sufficient number of patients as compared to the placebo. This takes time. It is enormously expensive to conduct a clinical trial as we all know. It is best to take time beforehand and take the best shot. Any company, especially a tiny company, should take the time to determine the clearest path to gain success for such an expensive endeavor.